ADMS - Adamas Pharmaceuticals provides preliminary Q4 and FY figures

Adamas Pharmaceuticals (ADMS) expects total revenue for Q4 to be $20.8M and $74.2M for FY 2020.Product sales of GOCOVRI is expected to be $19.8M for Q4, an increase of 21% from same quarter prior year and $71.2M for FY 2020.“I am proud of our team’s resilience, ability to adapt, and unwavering execution of our key priority to deliver GOCOVRI® to the Parkinson’s community. Through strong performance, GOCOVRI sales are expected to increase 30% for the full year 2020 against the backdrop of a challenging macro environment. Furthermore, we strengthened the foundation of our business for long-term, sustainable growth with key management and board additions. In 2021, our goal is to realize the potential of GOCOVRI and integrate OSMOLEX ER®; positioning both to benefit their unique patient populations, and to record a full year of royalties from sales of NAMZARIC®. We appreciate that market dynamics may remain fluid in 2021; however, we are highly encouraged

For further details see:

Adamas Pharmaceuticals provides preliminary Q4 and FY figures